Sex Differences in Clinical Characteristics and Outcomes After Myocardial Infarction With Low Ejection Fraction: Insights From PARADISE-MI.


Journal

Journal of the American Heart Association
ISSN: 2047-9980
Titre abrégé: J Am Heart Assoc
Pays: England
ID NLM: 101580524

Informations de publication

Date de publication:
05 09 2023
Historique:
medline: 6 9 2023
pubmed: 23 8 2023
entrez: 23 8 2023
Statut: ppublish

Résumé

Background Studies demonstrated sex differences in outcomes following acute myocardial infarction, with women more likely to develop heart failure (HF). Sacubitril/valsartan has been shown to reduce cardiovascular death and HF hospitalizations in patients with HF with reduced ejection fraction. Methods and Results A total of 5661 patients (1363 women [24%]) with acute myocardial infarction complicated by reduced left ventricular ejection fraction (≤40%), pulmonary congestion, or both and ≥1 of 8 risk-augmenting factors were randomized to receive sacubitril/valsartan or ramipril. The primary outcome was cardiovascular death or incident HF. Baseline characteristics, clinical outcomes, and safety events were compared according to sex, a prespecified subgroup. Female participants were older and had more comorbidities. After multivariable adjustment, women and men were at similar risks for cardiovascular death or all-cause death. Women were more likely to have first HF hospitalization (hazard ratio [HR], 1.34 [95% CI, 1.05-1.70];

Identifiants

pubmed: 37609931
doi: 10.1161/JAHA.122.028942
pmc: PMC10547323
doi:

Substances chimiques

sacubitril 17ERJ0MKGI
Ramipril L35JN3I7SJ
Valsartan 80M03YXJ7I

Banques de données

ClinicalTrials.gov
['NCT02924727']

Types de publication

Randomized Controlled Trial Journal Article Research Support, Non-U.S. Gov't Research Support, N.I.H., Extramural

Langues

eng

Sous-ensembles de citation

IM

Pagination

e028942

Subventions

Organisme : NHLBI NIH HHS
ID : T32 HL094301
Pays : United States
Organisme : British Heart Foundation
ID : RE/18/6/34217
Pays : United Kingdom

Références

Eur J Heart Fail. 2021 Jun;23(6):1040-1048
pubmed: 33847047
J Am Heart Assoc. 2019 May 21;8(10):e012161
pubmed: 31092091
JAMA. 2009 Aug 26;302(8):874-82
pubmed: 19706861
N Engl J Med. 1991 Jul 25;325(4):221-5
pubmed: 2057022
J Am Heart Assoc. 2017 Aug 21;6(8):
pubmed: 28862963
J Am Coll Cardiol. 2019 Nov 12;74(19):2379-2389
pubmed: 31699278
J Am Coll Cardiol. 2010 Mar 16;55(11):1057-65
pubmed: 20223363
Circ Cardiovasc Qual Outcomes. 2018 Feb;11(2):e004437
pubmed: 29449443
Circulation. 2021 Feb 23;143(8):e254-e743
pubmed: 33501848
Circulation. 2020 Dec 8;142(23):2231-2239
pubmed: 33249922
Circulation. 2012 Jul 31;126(5):604-11
pubmed: 22850362
J Am Coll Cardiol. 2006 Feb 7;47(3 Suppl):S4-S20
pubmed: 16458170
N Engl J Med. 1991 Jul 25;325(4):226-30
pubmed: 2057023
Eur Heart J Cardiovasc Pharmacother. 2017 Jul 1;3(3):163-182
pubmed: 28329228
Eur J Clin Pharmacol. 2018 Sep;74(9):1165-1173
pubmed: 29804162
Heart. 2007 Nov;93(11):1369-75
pubmed: 17933995
N Engl J Med. 2019 Oct 24;381(17):1609-1620
pubmed: 31475794
J Am Coll Cardiol. 2005 Mar 15;45(6):832-7
pubmed: 15766815
N Engl J Med. 2021 Nov 11;385(20):1845-1855
pubmed: 34758252
JAMA. 1996 Mar 13;275(10):777-82
pubmed: 8598594
Arch Intern Med. 2003 Oct 27;163(19):2345-53
pubmed: 14581255
JAMA Intern Med. 2014 Nov;174(11):1822-30
pubmed: 25265319
J Am Coll Cardiol. 2019 Dec 17;74(24):3013-3022
pubmed: 31865968
Circ Cardiovasc Qual Outcomes. 2015 Nov;8(6):586-92
pubmed: 26462876
Circulation. 2008 Dec 16;118(25):2803-10
pubmed: 19064680
Circ Res. 2016 Apr 15;118(8):1273-93
pubmed: 27081110
J Clin Pharmacol. 2016 Jan;56(1):78-86
pubmed: 26073563
CJC Open. 2021 Jul 01;3(12 Suppl):S19-S27
pubmed: 34993430
J Clin Epidemiol. 1995 Jun;48(6):851-7
pubmed: 7769416
Eur J Heart Fail. 2015 Mar;17(3):301-12
pubmed: 25655011
N Engl J Med. 2014 Sep 11;371(11):993-1004
pubmed: 25176015
J Am Coll Cardiol. 2006 Feb 7;47(3 Suppl):S21-9
pubmed: 16458167
Circulation. 2020 Feb 4;141(5):338-351
pubmed: 31736337
Lancet. 1992 Feb 8;339(8789):372
pubmed: 1346451
Lancet. 2004 Sep 11-17;364(9438):937-52
pubmed: 15364185

Auteurs

Xiaowen Wang (X)

Brigham and Women's Hospital Harvard Medical School Boston MA.

Karola S Jering (KS)

Brigham and Women's Hospital Harvard Medical School Boston MA.

Maja Cikes (M)

University Hospital Centre Zagreb Zagreb Croatia.

Mariya P Tokmakova (MP)

University Multiprofile Hospital for Active Treatment Sv. Georgi Medical University Plovdiv Plovdiv Bulgaria.

Roxana Mehran (R)

Mount Sinai School of Medicine New York NY.

Yaling Han (Y)

General Hospital of Northern Theater Command Shenyang China.

Cara East (C)

Texas Heart Center Dallas TX.

Freny Vaghaiwalla Mody (FV)

David Geffen School of Medicine at University of California, Los Angeles Veterans Affairs Greater Los Angeles Healthcare System Los Angeles CA.

Yi Wang (Y)

Novartis Pharmaceuticals Corporation East Hanover NJ.

Eldrin F Lewis (EF)

Stanford University School of Medicine Palo Alto CA.

Brian Claggett (B)

Brigham and Women's Hospital Harvard Medical School Boston MA.

John J V McMurray (JJV)

British Heart Foundation Glasgow Cardiovascular Research Centre University of Glasgow Glasgow Scotland United Kingdom.

Christopher B Granger (CB)

Duke University School of Medicine Durham NC.

Marc A Pfeffer (MA)

Brigham and Women's Hospital Harvard Medical School Boston MA.

Scott D Solomon (SD)

Brigham and Women's Hospital Harvard Medical School Boston MA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH